<p>Summit Therapeutics Inc.（納斯達克代碼：SMMT - 獲取免費報告）週一股價下跌 5.4%。該股最低交易價為 20.00 美元，最後交易價為 20.34 美元。在交易過程中，約有 583,844 股成交，較日均成交量 2,401,488 股下降了 76%。該股此前收盤價為 21.50 美元。</p>
<p>獲取 <strong>Summit Therapeutics</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<ul>
<li>MarketBeat 週報 – 11/4 - 11/8</li>
</ul>
<p>多家研究機構對 SMMT 發佈了報告。HC Wainwright 在 1 月 21 日的報告中重申了對 Summit Therapeutics 的 “買入” 評級，並設定了 44.00 美元的目標價。Truist Financial 在 1 月 8 日的研究報告中開始覆蓋 Summit Therapeutics，給予 “買入” 評級，目標價為 35.00 美元。Jefferies Financial Group 在 12 月 6 日的研究報告中開始覆蓋 Summit Therapeutics，設定了 “買入” 評級和 31.00 美元的目標價。JMP Securities 在 11 月 4 日的研究報告中開始覆蓋 Summit Therapeutics，給予 “市場表現優於大盤” 評級，目標價為 32.00 美元。最後，Wells Fargo &amp; Company 在 12 月 11 日的研究報告中開始覆蓋 Summit Therapeutics，設定了 “增持” 評級和 30.00 美元的目標價。一位分析師對該股給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat.com 的數據，該股的平均評級為 “適度買入”，共識目標價為 33.57 美元。</p>
<p><strong>獲取我們關於 SMMT 的最新報告</strong></p>
<h2>Summit Therapeutics 股票表現</h2>
<ul>
<li>Summit Therapeutics：他們的肺癌藥物是遊戲規則改變者嗎？</li>
</ul>
<p>該公司的市值為 153.2 億美元，市盈率為-74.21，貝塔值為-0.88。該公司的 50 日移動平均價格為 19.19 美元，200 日移動平均價格為 18.11 美元。</p>
<h2>對 Summit Therapeutics 的對沖基金看法</h2>
<p>幾家對沖基金最近增加或減少了對 SMMT 的持股。Baker BROS. Advisors LP 在第三季度將其在 Summit Therapeutics 的持股增加了 5.2%。Baker BROS. Advisors LP 目前持有該公司 24,424,865 股股票，價值 534,905,000 美元，在上個季度又購買了 1,202,643 股。abrdn plc 在第三季度獲得了 Summit Therapeutics 的新頭寸，價值 24,885,000 美元。FMR LLC 在第三季度將其在 Summit Therapeutics 的持股增加了 9.8%。FMR LLC 目前持有該公司 8,303,119 股股票，價值 181,838,000 美元，在上個季度又購買了 737,692 股。Charles Schwab Investment Management Inc.在第三季度將其在 Summit Therapeutics 的持股增加了 53.3%。Charles Schwab Investment Management Inc.目前持有該公司 1,432,713 股股票，價值 31,376,000 美元，在上個季度又購買了 497,984 股。最後，Principal Financial Group Inc.在第四季度將其在 Summit Therapeutics 的持股增加了 252.8%。Principal Financial Group Inc.目前持有該公司 205,150 股股票，價值 3,661,000 美元，在上個季度又購買了 147,003 股。目前，4.61% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Summit Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<ul>
<li>Summit Therapeutics 因試驗結果飆升：現在是買入時機嗎？</li>
</ul>
<p>Summit Therapeutics Inc.是一家生物製藥公司，專注於在美國和英國發現、開發和商業化對患者、醫生、護理人員和社會友好的藥物療法。該公司的主要開發候選藥物是 Ivonescimab，一種通過阻斷 PD-1 與抗血管生成相結合的免疫療法雙特異性抗體；其抗感染產品組合包括 SMT-738，一種用於治療多重耐藥感染的新型精準抗生素，主要包括耐碳青黴烯類的腸桿菌科感染。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Summit Therapeutics 更好</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>3 只必備 ETF 將在本季度主導市場</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>尋求穩定？這 3 只股票提供強勁潛力</li>
<li>如何投資藍籌股</li>
<li>貿易戰便宜股票：三大精選不容錯過</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Summit Therapeutics 嗎？</h2>
<p>在你考慮 Summit Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Summit Therapeutics 並不在名單上。</p>
<p>雖然 Summit Therapeutics 目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Summit治療

<p>Summit Therapeutics（納斯達克代碼：SMMT）股價下跌 5.4%，至 20.34 美元，交易量較平均水平下降 76%。分析師們對其前景持積極態度，多家機構給予 “買入” 評級，目標價格範圍在 30 美元至 44 美元之間。該股票的平均評級為 “適度買入”，共識目標價格為 33.57 美元。對沖基金也調整了在該公司的持股，該公司專注於開發針對各種醫療條件的療法，包括用於免疫治療的雙特異性抗體和精準抗生素</p>

<p>Summit Therapeutics Inc. (NASDAQ:SMMT - Get Free Report) shares dropped 5.4% on Monday . The stock traded as low as $20.00 and last traded at $20.34. Approximately 583,844 shares traded hands during trading, a decline of 76% from the average daily volume of 2,401,488 shares. The stock had previously closed at $21.50.</p>
<div class="lb-trans"><p>Summit Therapeutics Inc.（納斯達克代碼：SMMT - 獲取免費報告）週一股價下跌 5.4%。該股最低交易價為 20.00 美元，最後交易價為 20.34 美元。在交易過程中，約有 583,844 股成交，較日均成交量 2,401,488 股下降了 76%。該股此前收盤價為 21.50 美元。</p>
</div><p>Get <strong>Summit Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Summit Therapeutics</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>MarketBeat Week in Review – 11/4 - 11/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 11/4 - 11/8</li>
</ul>
</div><p>A number of research firms have issued reports on SMMT. HC Wainwright reiterated a &#34;buy&#34; rating and set a $44.00 target price on shares of Summit Therapeutics in a report on Tuesday, January 21st. Truist Financial began coverage on Summit Therapeutics in a research note on Wednesday, January 8th. They issued a &#34;buy&#34; rating and a $35.00 price objective on the stock. Jefferies Financial Group started coverage on Summit Therapeutics in a research note on Friday, December 6th. They set a &#34;buy&#34; rating and a $31.00 target price for the company. JMP Securities started coverage on Summit Therapeutics in a research report on Monday, November 4th. They issued a &#34;market outperform&#34; rating and a $32.00 price target on the stock. Finally, Wells Fargo &amp; Company began coverage on Summit Therapeutics in a research report on Wednesday, December 11th. They set an &#34;overweight&#34; rating and a $30.00 price objective for the company. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $33.57.</p>
<div class="lb-trans"><p>多家研究機構對 SMMT 發佈了報告。HC Wainwright 在 1 月 21 日的報告中重申了對 Summit Therapeutics 的 “買入” 評級，並設定了 44.00 美元的目標價。Truist Financial 在 1 月 8 日的研究報告中開始覆蓋 Summit Therapeutics，給予 “買入” 評級，目標價為 35.00 美元。Jefferies Financial Group 在 12 月 6 日的研究報告中開始覆蓋 Summit Therapeutics，設定了 “買入” 評級和 31.00 美元的目標價。JMP Securities 在 11 月 4 日的研究報告中開始覆蓋 Summit Therapeutics，給予 “市場表現優於大盤” 評級，目標價為 32.00 美元。最後，Wells Fargo &amp; Company 在 12 月 11 日的研究報告中開始覆蓋 Summit Therapeutics，設定了 “增持” 評級和 30.00 美元的目標價。一位分析師對該股給予了持有評級，六位分析師給予了買入評級。根據 MarketBeat.com 的數據，該股的平均評級為 “適度買入”，共識目標價為 33.57 美元。</p>
</div><p><strong>Get Our Latest Report on SMMT</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 SMMT 的最新報告</strong></p>
</div><h2>Summit Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Summit Therapeutics 股票表現</h2>
</div><ul>
<li>Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics：他們的肺癌藥物是遊戲規則改變者嗎？</li>
</ul>
</div><p>The firm has a market capitalization of $15.32 billion, a price-to-earnings ratio of -74.21 and a beta of -0.88. The company has a 50-day moving average price of $19.19 and a 200-day moving average price of $18.11.</p>
<div class="lb-trans"><p>該公司的市值為 153.2 億美元，市盈率為-74.21，貝塔值為-0.88。該公司的 50 日移動平均價格為 19.19 美元，200 日移動平均價格為 18.11 美元。</p>
</div><h2>Hedge Funds Weigh In On Summit Therapeutics</h2>
<div class="lb-trans"><h2>對 Summit Therapeutics 的對沖基金看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in SMMT. Baker BROS. Advisors LP boosted its holdings in shares of Summit Therapeutics by 5.2% in the 3rd quarter. Baker BROS. Advisors LP now owns 24,424,865 shares of the company's stock valued at $534,905,000 after buying an additional 1,202,643 shares in the last quarter. abrdn plc acquired a new position in Summit Therapeutics in the third quarter valued at $24,885,000. FMR LLC boosted its stake in Summit Therapeutics by 9.8% in the third quarter. FMR LLC now owns 8,303,119 shares of the company's stock valued at $181,838,000 after acquiring an additional 737,692 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Summit Therapeutics by 53.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,432,713 shares of the company's stock worth $31,376,000 after purchasing an additional 497,984 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Summit Therapeutics by 252.8% in the 4th quarter. Principal Financial Group Inc. now owns 205,150 shares of the company's stock valued at $3,661,000 after purchasing an additional 147,003 shares during the last quarter. 4.61% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金最近增加或減少了對 SMMT 的持股。Baker BROS. Advisors LP 在第三季度將其在 Summit Therapeutics 的持股增加了 5.2%。Baker BROS. Advisors LP 目前持有該公司 24,424,865 股股票，價值 534,905,000 美元，在上個季度又購買了 1,202,643 股。abrdn plc 在第三季度獲得了 Summit Therapeutics 的新頭寸，價值 24,885,000 美元。FMR LLC 在第三季度將其在 Summit Therapeutics 的持股增加了 9.8%。FMR LLC 目前持有該公司 8,303,119 股股票，價值 181,838,000 美元，在上個季度又購買了 737,692 股。Charles Schwab Investment Management Inc.在第三季度將其在 Summit Therapeutics 的持股增加了 53.3%。Charles Schwab Investment Management Inc.目前持有該公司 1,432,713 股股票，價值 31,376,000 美元，在上個季度又購買了 497,984 股。最後，Principal Financial Group Inc.在第四季度將其在 Summit Therapeutics 的持股增加了 252.8%。Principal Financial Group Inc.目前持有該公司 205,150 股股票，價值 3,661,000 美元，在上個季度又購買了 147,003 股。目前，4.61% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Summit Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Summit Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><ul>
<li>Summit Therapeutics Surges on Trial Results: Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>Summit Therapeutics 因試驗結果飆升：現在是買入時機嗎？</li>
</ul>
</div><p>Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.</p>
<div class="lb-trans"><p>Summit Therapeutics Inc.是一家生物製藥公司，專注於在美國和英國發現、開發和商業化對患者、醫生、護理人員和社會友好的藥物療法。該公司的主要開發候選藥物是 Ivonescimab，一種通過阻斷 PD-1 與抗血管生成相結合的免疫療法雙特異性抗體；其抗感染產品組合包括 SMT-738，一種用於治療多重耐藥感染的新型精準抗生素，主要包括耐碳青黴烯類的腸桿菌科感染。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Summit Therapeutics</li>
<li>How to Know if a Stock Pays Dividends and When They Are Paid Out</li>
<li>3 Must-Have ETFs Set to Dominate This Quarter</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>Seeking Stability? These 3 Stocks Offer Strong Potential</li>
<li>How to Invest in Blue Chip Stocks</li>
<li>Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Summit Therapeutics 更好</li>
<li>如何知道一隻股票是否支付股息以及何時支付</li>
<li>3 只必備 ETF 將在本季度主導市場</li>
<li>什麼是二次公開募股？投資者需要知道什麼</li>
<li>尋求穩定？這 3 只股票提供強勁潛力</li>
<li>如何投資藍籌股</li>
<li>貿易戰便宜股票：三大精選不容錯過</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Summit Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Summit Therapeutics 嗎？</h2>
</div><p>Before you consider Summit Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Summit Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦現在購買，以便在更廣泛的市場注意到之前……而 Summit Therapeutics 並不在名單上。</p>
</div><p>While Summit Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Summit Therapeutics 目前在分析師中獲得了 “適度買入” 的評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Summit 治療 (NASDAQ:SMMT) 股價下跌 5.4% - 以下是原因